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Abstract
Background
D-dimer levels measured during and after vitamin K antagonist withdrawal may be used in
clinical practice to assess the individual risk of recurrent venous thromboembolism. Cur-
rently, direct oral anticoagulants (DOACs) are frequently used in venous thromboembolism
treatment; however, their pharmacokinetics and pharmacodynamics characteristics are
completely different than vitamin K antagonists. The present study aimed at comparing the
results of D-dimer levels during and after anticoagulation withdrawal in patients with venous
thromboembolism treated with DOACs or warfarin.
Material and methods
D-dimer levels were measured in 527 patients (“cases”) during DOACs treatment (T0) and
after 15 (T15), 30 (T30), 60 (T60) and 90 (T90) days after their discontinuation and in 527
patients (“controls”) enrolled in the DULCIS study (all treated with warfarin), matched for
sex, age (+/-3 y), type of D-dimer assay and site of venous thromboembolism. Both cases
and controls received anticoagulant treatment after a first venous thromboembolism event
that was unprovoked or associated with weak risk factors.
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Results
The rate of positive D-dimer results was significantly higher in cases than in controls at T0
(10.8% vs 5.1%, p = 0.002) and at T30 (18.8% vs 11.8%, p = 0.019), as well as at the other
time-points, though not statistically significant.
Conclusion
D-dimer levels during and after stopping an anticoagulant treatment for a venous thrombo-
embolism episode differ between patients treated with a DOAC than in those treated with
warfarin. Specifically designed prospective studies are warranted to reassess the use of D-
dimer as predictor of the risk of recurrent venous thromboembolism in patients treated with
DOACs.
Introduction
Venous thromboembolism (VTE), that includes deep vein thrombosis (DVT) and/or pulmo-
nary embolism (PE), is a frequent, severe, acute disease. After the first episode, VTE has a risk
to recur that increases sharply after anticoagulation is stopped, especially in patients with
unprovoked events. Anticoagulant therapy is absolutely necessary to treat the acute phase of
the disease, to avoid early complications, and it is also indicated in the long term to avoid
recurrences. Clinical studies have shown that three months of initial treatment reduce the risk
of recurrence over a shorter period of anticoagulation [1]. However, whatever the duration of
the anticoagulant treatment thereafter, the protective benefit fades after anticoagulation is
stopped and the risk of recurrence increases again in higher risk patients [2–5]. Clinical prac-
tice guidelines therefore recommend at least 3 months of anticoagulation after a first unpro-
voked VTE; and in patients at high risk of recurrent VTE and non-high risk of bleeding,
indefinite (potentially lifelong) treatment is recommended [6]. The same guidelines suggest
stratifying patients according to risk of recurrent VTE, using D-dimer testing, a fibrin degra-
dation product and a marker of coagulation activation. Positive D-dimer results identify
patients with a high risk for recurrence (because of a persistent pro-thrombotic tendency) in
whom indefinite anticoagulation is justified [7]. Conversely, negative D-dimer may indicate
patients at low risk of recurrence, in whom extended anticoagulation may be unjustified [8].
D-dimer use for this proposal has been investigated and confirmed by many clinical studies.
In most of the studies, D-dimer level was measured from 3 to 4 weeks after anticoagulation
was stopped; in some studies D-dimer were measured serially during and at different times
after anticoagulation was stopped [9–11]; finally, in one study measurement was made only
during anticoagulant therapy [12]. It is noteworthy to stress that all the currently available
studies on D-dimer measurement to assess the risk of recurrent VTE events included only
patients receiving vitamin K antagonists (VKAs, in most cases warfarin) as oral anticoagulant
drug. In recent years, different oral anticoagulant drugs (direct oral anticoagulants, DOACs),
have increasingly been used for VTE treatment instead of VKAs. Currently, it is not known
whether D-dimer levels may have the same pattern during and after anticoagulation is stopped
in patients treated with DOACs, drugs that have pharmacokinetics and pharmacodynamics
characteristics completely different from VKAs.
The present study aimed at assessing the results of D-dimer levels during and after anticoa-
gulation is stopped in VTE patients treated with DOACs, in comparison with the D-dimer
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changes recorded in patients treated with warfarin who were included in the DULCIS study,
in which serial D-dimer measurements were used to decide on management of anticoagulant
therapy duration in patients after unprovoked VTE events [11].
Materials and methods
Patient populations
The present is a retrospective, case-control study, focusing on D-dimer level changes during
and after anticoagulant treatment was stopped in patients who received either DOACs or war-
farin for VTE therapy. The present study does not address the predictive value for VTE recur-
rence of D-dimer testing. The “cases” were VTE patients treated with DOACs who were
evaluated to manage the duration of anticoagulant treatment (see below). The “controls” were
matched patients selected among the patients included in the DULCIS study who were treated
with warfarin [11]. Both cases and controls received anticoagulant treatment after a first VTE
episode, that could be unprovoked or associated with weak risk factors that included: minor
general, laparoscopic, or arthroscopic surgery; pregnancy or puerperium; hormonal con-
traceptive or replacement therapy; long travel (> 6 hours); minor trauma, leg injury, reduced
mobility or hospitalization in a medical ward. The DULCIS patients followed a protocol based
on serial D-dimer measurements at the following time intervals: during anticoagulation (T0),
and 15 (T15), 30 (T30), 60 (T60), and 90 (T90) days after its suspension. As soon as the first
positive D-dimer was recorded, patients were recommended to continue or resume anticoagu-
lant therapy (at the time of the study only VKAs were available for chronic therapy). Those
with persistently negative D-dimer permanently interrupted anticoagulation. D-dimer mea-
surements were performed in the participant centers by using the quantitative assay customar-
ily adopted in the centers and results are available in the central database.
To realize this study, we asked some Italian centers, which routinely adopted a serial D-
dimer measurement procedure to decide the duration of anticoagulant therapy in VTE
patients treated with DOACs, if they were willing to centralize to the coordinating center the
characteristics of the patients (in anonymous way), and the quantitative results of D-dimer
measurements. A positive answer was obtained from 9 centers, which contributed to the study
by sending data from examined patients (“cases”).
Patients treated with warfarin were selected among patients enrolled in the DULCIS study
(registered at clinicaltrials.gov as #NCT00954395) and those treated with DOACs were included
in the START-Register (#NCT02219984). The DULCIS study and the START-Register have
been approved by the Ethical Committee of the coordinating center (Azienda Ospedaliero-Uni-
versitaria, Policlinico S. Orsola-Malpighi, Bologna, Italy). The local Ethics Committees approval
was then obtained by all participating centers. All patients provided informed written consent
to have data from their medical records used in research. Data were fully anonymized before
transferring to the central analysis office.
Matching procedure
The cases (subjects treated with DOACs), gathered from the 9 participating centers, were listed
onto an electronic page and printed to show only the fields to be used to select the appropriate
matching controls (treated with warfarin as VKA), following this order: the commercial assay
used to perform D-dimer measurements (see Table 1), sex, age (+- 3 years), and type of index
event (DVT, DVT + PE, isolated PE). The control subjects were selected in the coordinating
center from the general DULCIS database. The fields relevant for the selection, were copied
onto an electronic page and printed following the order detailed above. An author (C.L.) of the
study, unaware of all the remaining information contained in the database, was responsible for
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selecting a matched control for each case. We decided to do not match cases and controls for
the duration of previous anticoagulant treatment since in the DULCIS study it was demon-
strated that this characteristic did not influence the prevalence of positive or negative D-dimer
results [11].
The definition of positive/negative D-dimer results
Differently than in the DULCIS study, in the present report, positive or negative D-dimer
results were established using the cut-off values indicated for VTE exclusion by the commer-
cial D-dimer assays. Results were therefore considered positive when > 230 ng/ml for the
assays expressing results as D-dimer units and> 500 ng/ml for those using fibrinogen equiva-
lent units (FEU) as expression of results. D-dimer results were considered positive when above
the mentioned cut-off values.
Statistical analysis
Continuous variables are presented as median and interquartile range. The Mann-Whitney U-
test and the Chi-square test (Yates corrected) were used for group comparison, as appropriate;
Table 1. Baseline characteristics of patients treated with DOACs (cases) or warfarin (controls).
Characteristic Cases
n = 527
Controls
n = 527
P
Male sex, n. (%) 323 (61.3) 323 (61.3) 1.000
Age (y), median (IQ) 58 (46–71) 60 (46–71) 0.482
Age > 70 y, n. (%) 141 (26.8) 141 (26.8) 1.000
Type of VTE, n. (%)
Proximal DVT (no PE) 291 (55.2) 289 (54.8) 0.896
Proximal DVT with symptomatic PE 128 (24.3) 125 (23.7) 0.820
Isolated PE 108 (20.5) 113 (21.5) 0.690
Presence and type of risk factor, n. (%)
No risk factors (unprovoked) 365 (69.3) 385 (73.1) 0.173
Weak risk factors 162 (30.7) 142 (26.9)
Commercial D-dimer assays (results in FEU), n.
Innovance D-dimer (Siemens) 28 28
Sta Liatest D-Di (Diagnostica Stago) 241 241
VIDAS D-Dimer (bioMerieux) 2 2
Commercial D-dimer assays (results in D-dimer units), n.
HemosIL D-Dimer HS (Werfen) 256 256
Type of DOAC, n.
Apixaban 2.5 mg/2 die 11
Apixaban 5.0 mg/2 die 92
Dabigatran 110 mg/2 die 1
Dabigatran 150 mg/2 die 41
Edoxaban 30 mg/die 3
Edoxaban 60 mg/die 27
Rivaroxaban 15 mg/die 6
Rivaroxaban 20 mg/die 346
DVT = deep vein thrombosis; DOACs = direct oral anticoagulants; FEU = fibrinogen equivalent units;
PE = pulmonary embolism; VTE = venous thromboembolism
https://doi.org/10.1371/journal.pone.0219751.t001
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all p values less than 0.05 were considered to indicate statistical significance. For statistical
analysis the SPSS software package (SPSS, Chicago, III, USA) and the GraphPad Software (San
Diego, CA, USA) were used.
Results
We collected the results of 527 VTE patients (“cases”), who were receiving a treatment with a
DOAC. These patients had started a serial D-dimer measurement procedure to decide whether
to continue or resume anticoagulation if and when D-dimer assay resulted positive. Among
them, 66.8% were receiving Rivaroxaban (the first DOAC approved for this indication in our
country), 19.5% Apixaban, 8.0% Dabigatran and 5.7% Edoxaban; 21/527 were treated with the
corresponding low dose of DOACs. An equal number of VTE patients, receiving warfarin
(“controls”), were selected by means of the matching procedure detailed in Methods section.
The characteristics of the two cohorts are shown in Table 1.
As shown in Fig 1, the rate of positive D-dimer results was higher in cases than in controls
at T0: 10.8% vs 5.1%, respectively, p = 0.002, and at T30: 18,8% vs 11.8%, p = 0.019. Though
always higher in cases, the rates were not significantly different in the other time-point
measurements.
When the results obtained at T0 (during treatment) were analyzed in details, it was found
(Table 2) that significantly higher rates of positive di D-dimer in cases were detected in young
subjects (aged 70 years or less), when the index event was unprovoked, was represented by
Fig 1. Prevalence of positive D-dimer at different time-points in patients treated with DOACs (cases) or warfarin (controls). T0 = during anticoagulation;
T15, T30, T60 and T90 = 15, 30, 60 and 90 days after anticoagulation withdrawal, respectively.
https://doi.org/10.1371/journal.pone.0219751.g001
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DVT with or without PE, and when the assays used for D-dimer measurement were those
using FEU to express results.
The rates of positive D-dimer at different time-points resulted high in the small group of
cases (21 subjects) treated with reduced DOAC doses (T0 = 18.2%, T15 = 40.0%, T30 = 60.0%,
T90 = 50.0%). As expected, the age of these subjects was significantly higher than that of
patients who received standard doses (median age 68 y; IQR 52–79.5 y; vs 58 y; IQR 46–71,
respectively; p = 0.039). After exclusion of the cases treated with reduced DOAC doses, the
difference at T0 (during anticoagulation) between positive D-dimer rates in standard dose
DOAC-treated cases and controls did not change (Table 2).
No differences in the rates of positive D-dimer at the different time-points were found
between patients treated with once or twice per day DOAC dosing (Table 3).
Discussion
This study investigates, for the first time, the course of D-dimer levels in patients with VTE
treated with DOACs, measured during and after stopping anticoagulation. The rate of
Table 2. Prevalence of patients with positive D-dimer measured during treatment (T0) in patients treated with
DOACs (cases) or warfarin (controls).
Patients with positive
D-dimer (%) during
treatment (T0)
P
Cases Controls
All patients 10.8 5.1 0.002
Patients after exclusion of those treated with low-dose DOACs (n. 506) 10.2 5.1 0.002
Males 9.4 4.5 0.029
Females 12.9 6.1 0.036
Age <= 70 years 8.3 1.3 <0.0001
Age > 70 years 21.5 15.4 0.334
Unprovoked events 11.1 5.3 0.033
WRF-associated events 10.1 4.4 0.082
DVT+/-PE 11.0 5.5 0.010
Isolated PE 9.7 3.7 0.110
Assay reporting results as FEU 21.8 6.6 0.0001
Assays reporting results as D-dimer units 7.1 3.6 0.084
DVT = deep vein thrombosis; DOACs = direct oral anticoagulants; FEU = fibrinogen equivalent units;
PE = pulmonary embolism; VTE = venous thromboembolism; WRF = weak risk factor
https://doi.org/10.1371/journal.pone.0219751.t002
Table 3. Prevalence of positive D-dimer at different time-points in patients treated with once (Rivaraxaban and
Edoxaban) or twice (Dabigatran and Apixaban) per day dosing. T0 = during anticoagulation; T15, T30, T60 and
T90 = 15, 30, 60 and 90 days after anticoagulation withdrawal, respectively.
Patients with positive D-dimer (%) P
Once per day DOACs
n = 382
Twice per day DOACs
n = 145
T0 9.0% 15.1% 0.453
T15 24.4% 33.1% 0.087
T30 17.7% 20.2% 0.609
T60 10.0% 10.0% 0.511
T90 10.1% 7.1% 0.633
https://doi.org/10.1371/journal.pone.0219751.t003
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positive D-dimer assessed during anticoagulation was significantly higher in patients treated
with DOACs than warfarin. After anticoagulation was stopped, the rates of positive D-dimer
in the subsequent time measurements were still higher in DOACs than in warfarin, though
difference reached a statistical significance only at the 30 days measurement control. While
the higher prevalence of positive D-dimer during treatment with DOACs than with warfarin
can be interpreted as a result of the completely different mechanism of action on coagulation
balance of the two types of anticoagulant agents, more difficult is to hypothesize an explana-
tion for the different prevalence of positive results that was detected at a later time after
anticoagulation was stopped. It can be surmised that, similarly to what occurs in some warfa-
rin-treated patients whose D-dimer measurements become positive at different time after
the treatment is stopped, even in DOAC-treated patients laboratory signs of hypercoagula-
bility may appear at a later time after treatment withdrawal, and more frequently than in
warfarin-treated patients due to a putative higher baseline condition of activated coagula-
tion. The high prevalence of positive D-dimer results among the few patients who were
treated with reduced DOAC doses, was likely due to the selection of elderly patients (in
whom D-dimer levels are in general increased) for the reduced dose-treatment. Focusing
on results obtained during anticoagulation (T0, Table 2), positive D-dimer results were sig-
nificantly more frequent in DOAC-treated patients than in controls when patients were
younger, had unprovoked events and when the index event was DVT with/without PE; fur-
thermore, the difference was particularly relevant when D-dimer levels were measured using
assays reporting results as FEU. This finding suggests a possible influence of the various D-
dimer assays on results obtained in patients who are anticoagulated with warfarin or DOACs
and deserves further assessment.
The presence of high D-dimer plasma levels is in general considered a sign of hypercoagula-
bility [13]. D-dimer assay has several indications in clinical laboratory, particularly in the diag-
nostic process to exclude VTE in symptomatic patients. More recently, D-dimer testing is also
being used to assess the individual risk of VTE recurrence, to recommend extended anticoagu-
lation in patients in whom positive test results indicate a high risk of recurrence [7, 8, 11]. Our
results suggest that more patients treated with DOACs would receive indication for extended
anticoagulation than those treated with warfarin and that a sign of hypercoagulability during
treatment is more frequent in the former than in the latter patients.
The most important limitation of this study is that we do not have data about comparison
of VTE recurrences according to D-dimer levels during and after stopping anticoagulant treat-
ment, since we did not collect follow-up in patients treated with DOACs. Other important lim-
itations are: the retrospective design, the indirect comparison with a warfarin-treated control
group derived from a different study, the potential persisting effects of factors not included in
the matching procedure, the imbalance between patients receiving the different DOAC drugs
(with a high prevalence of rivaroxaban, the first DOAC admitted in our country for VTE indi-
cation), the relatively not high number of examined patients, and the non-centralized D-dimer
determination, that was performed in the participating centers using different commercial
assays.
The present study does not show any data regarding the risk of recurrent VTE after stop-
ping anticoagulant therapy with either DOACs or warfarin according to the results of D-dimer
measurements. Our results should, therefore, only be considered as hypothesis generating for
specifically designed, prospective studies to assess the presence and potential clinical effects of
signs of hypercoagulability during DOAC treatment in VTE patients; they also indicate that
the use of D-dimer to predict the risk of VTE recurrence should be reassessed in patients
treated with DOACs.
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